Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Ni...( 2008 and October 3 2009 include appr...),Health

Date:11/4/2009

, 2008 and October 3, 2009 include approximately 7.3 million shares underlying its convertible notes as they were dilutive for the respective quarters. The following table reconciles the specific items excluded from GAAP gross profit and gross margin in the calculation of non-GAAP gross profit and gross margin for the periods shown below: THORATEC CORPORATION Reconciliation of GAAP to Non-GAAP Gross Profit (Unaudited) (in thousands) Three Months Ended Nine Months Ended ------------------ ----------------- October September October September 3, 27, 3, 27, 2009 2008 2009 2008 ---- ---- ---- ---- Gross profit on a GAAP basis $53,732 61.1% $48,770 60.3% $158,514 58.8% $135,430 59.4% Share-based compensation expense 515 371 1,534 1,284 --- --- ----- ----- Gross profit on a non-GAAP basis $54,247 61.7% $49,141 60.8% $160,048 59.4% $136,714 60.0% ======= ======= ======== ======== The following table reconciles the specific items excluded from GAAP operating expenses in the calculation of non-GAAP operating expenses for the periods shown below: THORATEC CORPORATION Reconciliation of GAAP to Non-GAAP Operating Expenses (Unaudited) (in thousands) Three Months Ended Nine Months Ended
'/>"/>

SOURCE Thoratec Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA